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HIV-1 associated neurocognitive disorders (HAND) affect about 15-55% of HIV positive 
patients to date; and although the traditional form of therapy, combined antiretroviral therapy 
(cART), has been sufficient to suppress the more severe dementia-causing form of HAND, the 
proportion of seropositive patients experiencing minor neurocognitive disorders (MND) or 
asymptomatic neurocognitive impairments (ANI) due to HAND, has not changed. While cART 
therapy is inefficient in treating MND- and ANI-related HAND and its underlying 
synaptodendritic pruning pathology, cART does however decrease the occurrence of HIV-related 
encephalitis. This link neurocognitive decline to functional deficits in brain-wise microstructure 
and the characteristic degenerating synaptodendritic pruning morphology. HIV-1 neurotoxic 
transactivator of transcription (Tat) protein expression alone recapitulates this degenerative 
synaptic morphology and neuronal pathology. Thus, we utilized a Tat transgenic mouse model in 
this study to investigate the longitudinal effects of Tat on ubiquitous synaptic density in vivo. 
Positron-emission tomography (PET) imaging of the synaptic vesicle glycoprotein 2A (SV2A) 
selective radiotracer [11C]-UCB-J, over three months, indicate a downregulation of SV2A in the 
frontal cortex of transgenic Tat(+) mice compared to Tat(−) controls over time. These findings 
suggest a decrease in synaptic density due to Tat expression, which might be a suitable 
biomarker for early disease progression in HIV-1 infection. 
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CHAPTER 1: INTRODUCTION 
Human immunodeficiency virus type 1 (HIV-1)-associated neurocognitive disorder 
(HAND) 
The World Health Organization estimates 36.7 million people are diagnosed with human 
immunodeficiency virus type 1 (HIV-1) worldwide, which has been considered a fatal diagnosis 
before antiretroviral treatments were established.  With the introduction of combined 
antiretroviral therapy (cART), HIV-1 infection has changed from a death sentence to a 
manageable condition with decreased mortality rates and increased life expectancies1-3. For 
example, the development and treatment of HIV-1 with cART has decreased the prevalence of 
acquired immunodeficiency syndrome (AIDS)-related deaths by 50%2.  However, as cART is 
not able to eradicate the effects on the central nervous system (CNS), HIV-1 is now considered a 
chronic disease that specifically targets the brain with at least 15-55 office seropositive 
individuals experiencing some form of HIV-1-associated neurocognitive disorders (HAND)4-7. 
HAND consists of three subtypes: the more severe HIV-associated dementia (HAD), minor 
neurocognitive disorder (MND), and asymptomatic Neuro cognitive impairment (ANI)2. cART 
treatment has significantly decreased the incidence of the more severe form of HAND, HAD, by 
40-50%, but the milder forms, MND or ANI, remain the same in the post-cART era3-7, indicating 
cART’s therapeutic inefficiency against HAND, especially for the milder forms. Not only this, 
but cART treatment also accelerates toxicity and dysfunction over long-term use8.
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The severity of the pathophysiology underlying MND and ANI are thought to be more 
associated with functional neurological changes rather than encephalitis, including increased 
subtle changes in gray matter volume as well as supporting white matter microstructures that 
become apparent with age, marking depressed synaptic communication9. Additionally, post-
mortem tissue analyses on HIV-1 infected patients with MND and ANI indicate specific effects 
on synaptic connectivity, including dendritic beading, synaptic degeneration, dendritic spine loss, 
and axonal disruption; all important machineries for cell communication, neurological function, 
and cognition10. HIV-1 contributes to these observed neuronal deficits through the continued 
production of neurotoxic HIV-1 proteins, including the transactivator of transcription (Tat). Tat 
is released from cellular reservoirs within the CNS of cART-treated HIV patients11. Importantly, 
cART treatment seems to have little or no effect on the secretion rate of Tat from infected cells 
in the CNS as Tat remains present in the blood of HIV-1 patients, extending viral replication and 
HAND pathology11,12. 
 
HIV-1 transactivator of transcription (Tat) 
Tat is a regulatory protein within the genome of HIV-1 that drastically enhances the 
efficiency of viral transcription, hence the name “Trans-Activator of Transcription” (Tat). 
Although Tat is not produced within neurons, it is one of the first toxic proteins expressed from 
macrophages and glial cells after HIV-1 infection occurs and is a contributor to the 
synaptodendritic injury observed in HIV-1 infected individuals2,13,14. Tat has been shown to 
cause structural and functional neuronal defects in vitro15-18 and in vivo19-23. For example, Tat has 
been shown to stimulate neurons, cause increases in [Ca2+]i, overproduction of free radicals, and 
disruption of neurotransmitter homeostasis, all of which likely leads to synaptodendritic 
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injury18,24-27. The expression of Tat in transgenic mice also recapitulates axonal and synaptic 
degeneration similar to that observed in cART-treated patients with MND and ANI19. Expression 
of Tat in these transgenic mice demonstrated to significantly reduce motor cortical thickness as 
well as axonal and synaptic vesicle proteins, respectively: the neuronal microtubule marker βIII-
Tubulin, presynaptic vesicle protein synaptophysin, and postsynaptic density 95 (PSD-95) 
protein; all associated with synaptodendritic injury caused by Tat expression 28. Nevertheless, it 
is unknown how Tat is targeted at the pre-synapse to produce these pathological changes, which 
is the focus of the present study.  
 
SV2A PET radiotracer [11C]-UCB-J 
Synaptic vesicle glycoprotein 2A (SV2A) is a 12-transmembrane protein found within 
synaptic vesicles in neurons and in endocrine cells of the peripheral nervous system29. It is one of 
three isoforms, SV2A, SV2B, and SV2C all of which are expressed within different regions of 
the brain30. The function and mechanism of SV2A is not well understood; however, the 
membrane bound protein has been implicated in epilepsy and neuro-cognition via its critical role 
in ubiquitous neurotransmission31. Lack of SV2A results in seizures and death marking its 
necessity for life and neuro-communication or transmission32. SV2A has also been shown to be a 
good biomarker of pre-synaptic density and neurocognitive impairment or injury.  
Because of the importance of the SV2A involved in many neurological diseases, non-invasive 
imaging techniques to monitor and quantify the level of SV2A using have been developed in 
recent years. PET imaging has been chosen as the most effective tool due to its high sensitivity 
capable to detect in pico-molar concentration changes. Several PET tracers such as the SV2A 
ligands have been developed since 2015. Among them, [11C]-UCB-J has been identified as the 
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most promising probe with high affinity and sufficient penetration to the blood-brain-barrier. It 
was first reported and evaluated in rhesus macaque model29. [11C]-UCB-J biodistribution study 
demonstrated high uptake in all grey matter regions with fast kinetics, and blocking study also 
demonstrated its high specificity as a SV2A ligand29.  Recently [11C]-UCB-J PET imaging has 
been evaluated in human subjects29 and rodent models33,34. Significant hippocampal reductions in 
[11C]-UCB-J correlated with mild neurocognitive impairment and dementia in Alzheimer’s 
patients35 to demonstrate the ligand’s proficiency as a global pre-synaptic marker for injury. 
Further, the downregulation of synaptic density in the hippocampus via [11C]-UCB-J was also 
demonstrated in a preclinical mouse model of Alzheimer’s disease34. Therefore, PET analysis 
with the SV2A-brain-specific [11C]-UCB-J radioligand can provide a more thorough analysis of 
pre-synaptic density in the HAND-related Tat transgenic mouse model for future understanding 
of its mechanism of pathology. [11C]-UCB-J is also one of the first radioligands for a presynaptic 
marker, and therefore makes it distinct for dementia related diseases such as HAND36,  
Alzheimer’s disease, and even neuropsychiatric diseases 36.  
 
Present experimental study 
Loss of neuronal synaptic structure has been mostly reported within the excitatory 
nervous system of HAND studies, with more emphasis on a post-synaptic mechanism of Tat’s 
neurotoxic effects; however, there is limited understanding on HIV-1 Tat’s effect on global 
neuronal pre-synapses. Recent electrophysiology findings from our laboratory established Tat as 
a significant effector of GABAergic miniature inhibitory post-synaptic current (mIPSC) 
frequencies in the prefrontal cortex of Tat transgenic mice (manuscript currently under review). 
This decreasing effect on GABAergic mIPSC frequencies supports the idea for a negative Tat 
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effect on inhibitory pre-synaptic vesicular release. A previously published study further validates 
a pre-synaptic effect of HIV-1 Tat via a significant decrease in the pre-synaptic synaptotagmin II 
expression levels19. Notably, expression of synaptotagmin I at the pre-synapse is also critically 
dependent on the expression and co-trafficking of the synaptic vesicle glycoprotein SV2A, which 
is a brain-specific ubiquitous pre-synaptic vesicle membrane bound protein, and found at 
excitatory and inhibitory synapses critical for neurotransmission37. SV2A is critical for synaptic 
function as it is expressed ubiquitously in pre-synaptic secretory vesicles in all brain areas and its 
dysfunction has been implicated in epilepsy and Alzheimer’s disease38,39. With the recent 
development of the SV2A PET radiotracer [11C]-UCB-J, it has now been possible to measure 
synaptic density in humans, nonhuman primates, and rodents in vivo29,34,40. The use of the [11C]-
UCB-J ligand in our Tat transgenic mouse modeling HAND will therefore provide longitudinal 
information about changes in synaptic density with Tat expression. In the present study, I 
hypothesize that HIV-1 Tat disrupts synaptic density depending on exposure time, resulting in a 
downregulation of SV2A with chronic Tat exposure and therefore, a decrease in [11C]-UCB-J 
uptake. Understanding the exact mechanisms of Tat’s effect on the synapse can yield new targets 
for more efficient treatment against Tat related detrimental effects on the CNS and potentially 
HAND.  
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CHAPTER 2: MATERIALS AND METHODS 
Animals 
 HIV-1 Tat1-86 transgenic mice were used in the present study and developed on a 
C57BL/6J hybrid background. In this HIV-1 Tat transgenic mouse line HIV-1 Tat1-86 is 
expressed in astrocytes in a brain-specific, doxycycline (DOX) inducible manner41,42. The Tat 
transgenic mice are a well-established model for HAND since their neuropathology tends to 
mirror those observed in treated HIV+ patients with HAND , including structural 
abnormalities20,41, disrupted hippocampal circuitry19, as well as glial abnormalities41,42. 
Importantly, these mice and a related Tat transgenic mouse model develops changes in learning 
and memory relevant for HIV-1 patients19,21,41,43-45. Thus, chronic low level of Tat expression in 
this animal model is a good simulator of virally-suppressed, post-cART era HIV-1 treated 
patients, neurological damage, and the synaptodendritic decline experienced19,28. 
In the present study longitudinal PET imaging with [11C]-UCB-J was conducted on 
Tat(+) and control Tat(−) mice (n = 6 (3f)/per group)  at three time points (mean ± SD): baseline 
[prior to Tat induction; session 1 (S1)], 2 weeks post Tat induction [bvfbjnbC session 2 (S2)], 
and 3 months post Tat induction [session 3 (S3)]. In the female Tat(+) group one subject had to 
be excluded due to head movement artifacts during the 60 minutes of PET imaging. The 
demographics are summarized in Table 1. For baseline imaging, mice received normal chow 
(IsoPro RMH 3000, Purina LabDiet, St Louis, MO) and water available ad libitum before Tat 
induction to assess baseline SV2A expression. After baseline imaging, animals were fed a
specially formulated chow containing 6 mg/g DOX (Harlan, Indianapolis, IN, product #: 
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TD.09282) to induce Tat expression in mice that express the GFAP-rtTA and TRE-tat genes 
[Tat(+) mice]. Control Tat(−) transgenic mice that express only the GFAP-rtTA gene and lack 
the tat transgene received the same DOX diet after baseline PET imaging was conducted. 
Previous studies have shown increased astrocyte activation and elevations in caspase-3 as well as 
elevated tissue levels of CCL5/RANTES and IL-6 after only 2-day DOX exposure in Tat(+) 
mice compared to Tat(−) mice42,46.  Mice had free access to water and DOX food during the 
entire experimental study and were group housed (2-4 mice per cage) on a reversed 12 h 
light/dark cycle (lights on at 8:00 AM). All animal procedures were approved by the University 
of North Carolina Institutional Animal Care and Use Committee (IACUC) and are in keeping 
with ethical guidelines defined by the National Institutes of Health (NIH Publication No. 85-23). 
 
Positron emission tomography (PET) study 
Radioligand synthesis of [11C]-UCB-J 
The synthesis of [11C]-UCB-J was performed as previously described29. The [11C]-UCB-J 
probe was produced at the Biomedical Research Imaging Center Cyclotron and Radiochemistry 
Core facility according to the well-established radiosynthesis method29. Radiochemical purity 
was > 99% and the specific activity was 463.61 ± 108.78 GBq/μmol.  
 
Dynamic [11C]-UCB-J PET imaging 
All animal PET imaging paired with computed tomography (CT) scanning were 
performed during the daylight cycle and conducted in the Small Animal Imaging facility of the 
Biomedical Research Imaging Center at three time points: baseline prior Tat induction (S1), 2 
weeks post Tat induction (S2), 3 months post Tat induction (S3). PET/CT image acquisition was 
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performed using a small animal PET/CT scanner (SuperArgus, Sedecal Molecular Imaging, Inc. 
Spain) with a spatial resolution of 1.0 mm in the center field of view using 3D-ordered subject 
expectation maximization (3D-OSEM) reconstruction algorithm. The SuperArgus PET/CT 
system is equipped with the depth-of-interaction correction technique resulting in the reduction 
of resolution degradation along the trans-radial direction47, so that multi-animal imaging can be 
conducted with less radial distortion at the edge of the bore.   
Animals were anesthetized with inhalation of 1.5%-2.5% isoflurane-oxygen gas mixture. 
A tail vein catheter with 30 g needle was placed for each animal for the injection of radiotracer. 
The 12 mice were divided into 3 batches with 4 mice per batch (including both genotypes and 
both sexes per session). For each PET imaging, four mice were placed on a 4-bed mouse holder 
and securely attached to the nose cone supplied with 1.5-2.5% isoflurane-oxygen mixture. 
Respiration probe were placed near the chest of each mouse to monitor respiration rate, and a 
rectal temperature probe was placed to measure body temperature. A dose of [11C]-UCB-J (350 -
450 μCi in 150 μL saline) was administered through mouse tail vein. Simultaneously, a 60 
minute dynamic PET scan was acquired in list mode with energy window of 350-700 keV. After 
PET acquisition, a CT scan was conducted to obtain anatomical structure and attenuation 
correction. Anesthesia was maintained throughout the imaging and body temperature was 
maintained using a heat lamp.  Mice were recovered from anesthesia after imaging and returned 
back to the housing facility. A repeated PET/CT imaging was conducted at 2 weeks and 3 
months post Tat induction. The information of imaging animals at the three time points are 
summarized in Table 1. 
Following image acquisition, the raw dynamic PET data were binned into 19 time frames 
(6x10 s, 4x30 s, 2x60 s, 3x300 s, 4x600 s), and images were reconstructed using 3D-OSEM 
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algorithm (25 OSEM iterations) with corrections for scatter, random, decay, and attenuation. The 
resulting PET images were in 0.370x0.370x0.775 mm voxel size, and 120 mm axial field of 
view. Standardized uptake value (SUV) was calculated voxel-wise based on the injection dose 
(ID) and animal body weight (BW) with the formula: SUV=S/ID*BW (S is the radioactivity 
level per voxel).  Standard T2-weighted magnetic resonance images were acquired from eight 
Tat transgenic mice to form an averaged magnetic resonance imaging (MRI) atlas and provide 
the substructure reference within brain for the PET images.     
 
PET image analysis 
PET analysis was performed using PMOD 4.0 version (PMOD Technologies LLC, 
Switzerland). PET images were first registered to the MRI atlas images via co-registered CT 
images. Once co-registration was complete, the cerebrum was drawn in the MRI images as the 
volume of interest and superimposed to PET images to extract the time-activity curves of 
cerebrum from 19 time frames over 60 minutes. Similarly, SUVs were calculated for heart, liver 
and muscle. To assess group differences in the SUVs, the SUV of cerebrum was normalized to 
the SUV of muscle. The muscle uptake is used as a self-control to reduce the inter-subject errors 
in measuring injection doses and differences in plasma distributions. The brain to muscle ratios 
at the 17.5 and 25 minute time points when the uptake in brain reached plateau were compared 
among baseline, 2 weeks, and 3 months post Tat induction. Data are graphed as percentage 
change at 2 weeks and 3 months post induction to the baseline level. 
 
   10
Statistical analysis 
Data were analyzed by mixed-model analysis of variance (ANOVA) with time as a 
within-subjects factor (3 levels: S1, S2, S3), and genotype [2 levels: Tat(−), Tat(+)] and sex (2 
levels: males, females) as between-subjects factors followed by Bonferroni post hoc tests when 
appropriate (SPSS Statistics 25; IBM, Chicago, IL). Analyses were followed up with paired-
samples t-tests for significant interactions between time and genotype and/or sex. Differences 
of p-values ≤ 0.05 were considered statistically significant. All data are presented as mean ± the 
standard deviation of the mean (SD). 
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CHAPTER 3: RESULTS 
Time-activity SUV curves of [11C]-UCB-J PET over a year 60 minute time period 
 Average time-activity SUV curves of [11C]-UCB-J PET for each of the three sessions are 
presented separately for each genotype in Figure 2. SUVs for the cerebrum and muscle are 
shown separately. The time-activity SUV curves in the cerebrum for Tat(−) mice (Figure 2A) 
compared to Tat(+) mice (9 Figure 2B) show higher variability and less separation between 
sessions. For both genotypes the time-activity SUV curves show high [11C]-UCB-J ligand uptake 
in the cerebrum and low uptake in the muscle. No appreciable difference in the distribution or 
washout of the [11C]-UCB-J ligand is seen in the cerebrum or muscle for either genotype. 
Representative overlay images of a Tat(−) mouse and a Tat(+) mouse are presented in Figure 3. 
 
SUV for brain/muscle ratio at the static 17.5 minute time point 
Results of the SUV for brain/muscle ratio at 17.5 minutes PET scan are summarized in 
Figure 4.  A three-way mixed ANOVA revealed a significant main effect for time, F (2, 14) = 
8.95, p = .003, with a significant overall downregulation of SUV over PET sessions (S1 vs. S3: n 
= 11, p = .026; S2 vs. S3: n = 11, p = .049). The p-value of .026, infers that SV2A is overall 
decreased after 3 months of DOX treatment (S3) compared to baseline, when animals did not 
receive DOX treatment (S1). Further the p-value of .049 indicates that there was also a 
significant decrease seen after 3 months of DOX treatment (S3) compared to 2 weeks of DOX 
treatment (S2). More importantly however, this main effect of time is significantly altered by  
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genotype, indicated by a significant interaction between time and genotype, F (2, 14) = 3.91, p = 
.045, suggesting that DOX chow treatment, significantly alters [11C]-UCB-J uptake depending on 
whether DOX induces Tat expression [Tat(+) mice] or not [Tat(−) mice] (Figure 4A). Paired-
samples t-tests within each genotype demonstrate that the significant downregulation of SUV 
over time was only found with Tat expression in Tat(+) mice for baseline assessments prior Tat 
induction (S1) compared to 3 months post Tat induction (S3; n = 5, t(4) = 3.28, p = .031) and for 
assessments at 2 weeks post Tat induction (S2) compared to 3 months post Tat induction (S3; n = 
5, t(4) = 3.14, p = .035). In contrast, no significant differences were noted for Tat(−) mice 
between any time points. No other effect and/or interaction was significant, indicating that sex 
does not alter the brain/muscle ratio at the static 17.5 minute time point (Figure 4B-C). Overall, 
the findings suggest that [11C]-UCB-J uptake is decreased in Tat(+) mice compared to Tat(−) 
mice due to Tat induction significantly downregulating SV2A expression in the vesicles or pre-
synapses. Hence, pre-synaptic vesicles significantly decrease with Tat induction in Tat(+) mice 
when assessed in a longitudinal study, compared to Tat(−) mice that do not express the Tat 
protein. 
 
SUV for brain/muscle ratio at the static 25 minute time point  
Results of the SUV for brain/muscle ratio at 25 minutes PET scan are summarized in 
Figure 5.  A three-way mixed ANOVA revealed a significant main effect for time, F (2, 14) = 
8.57, p = .004, with a significant overall downregulation of SUV over PET sessions (S1 vs. S3: n 
= 11, p = .009). Importantly, there is a significant interaction between time and genotype, F (2, 
14) = 3.66, p = .053, with decreased SV2A uptake seen in Tat(+) mice but not Tat(−) mice 
(Figure 5A). Paired-samples t-tests within each genotype demonstrate a significant 
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downregulation of SV2A uptake in Tat(+) mice for baseline assessments prior Tat induction (S1) 
compared to 3 months post Tat induction (S3; n = 5, t(4) = 3.58, p = .023). In contrast, no 
significant differences were noted for Tat(−) mice between any time points. No other effect 
and/or interaction was significant, indicating that sex does not alter the brain/muscle ratio at the 
static 25 minute time point (Figure 5B-C). Thus, similar to the findings at 17.5 minutes, [11C]-
UCB-J uptake is decreased in Tat(+) mice compared to Tat(−) mice, which however was only 
noted between the first baseline PET session (S1) and the last session when Tat was induced for 
3 months (S3). 
 
SUV for brain/muscle ratio averaged across the static 17.5 and 25 minute time points  
Results of the SUV for brain/muscle ratio averaged across the two static 17.5 and 25 
minute time points are summarized in Figure 6.  A three-way mixed ANOVA revealed a 
significant main effect for time, F (2, 14) = 9.70, p = .002, with a significant overall 
downregulation of SUV over PET sessions (S1 vs. S3: n = 11, p = .012). Importantly, there is a 
significant interaction between time and genotype, F (2, 14) = 4.21, p = .037, with decreased 
SV2A uptake seen in Tat(+) mice but not Tat(−) mice (Figure 6A). Paired-samples t-tests within 
each genotype demonstrate a significant downregulation of SV2A uptake in Tat(+) mice for 
baseline assessments prior Tat induction (S1) compared to 3 months post Tat induction (S3; n = 
5, t(4) = 3.53, p = .024) and for assessments at 2 weeks post Tat induction (S2) compared to 3 
months post Tat induction (S3; n = 5, t(4) = 2.78, p = .050). In contrast, no significant 
differences were noted for Tat(−) mice between any time points. No other effect and/or 
interaction was significant, indicating that sex does not alter the brain/muscle ratio for the two 
time point averages (Figure 6B-C). Thus, these findings indicate that the uptake of the [11C]-
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UCB-J ligand over an 8 minute time period follows the trend demonstrated at the static 17.5 
minute time point, with a significant downregulation of SV2A expression between the first PET 
session at baseline (S1) and 3 months of Tat induction (S3), as well as between 2 weeks of Tat 
induction (S2) and S3. 
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CHAPTER 4: DISCUSSION 
HIV-1 associated neurocognitive disorder (HAND) post-cART – Overview 
Synapses are important for the function of the brain. In HIV-1 associated neurocognitive 
disorders (HAND), synapses are decreased partly due to the toxins released by the immune 
system in the brain and an over-excited or imbalanced neuronal system. Such toxins such as 
gp120, Nef, and Tat are released in different ways from the virus, either via microglia, 
macrophages, and astrocytes that are actively and inactively infected by HIV-148. While neurons 
are not directly infected, they undergo degeneration due to such toxins and excitotoxicity by 
mechanisms only partly known or acknowledged. 
Prior to cART therapy HIV-1 with encephalitis (HIVE) resulting from increased 
inflammation due to the infection of glial and the white blood cells previously mentioned, made 
up a larger amount of the HAND cases along with the most severe form, HAD. However, with 
cART treatment these forms of HAND have decreased and the less severe form MND,  persist 
with less occurrences of encephalitis; meaning, the disease within these less severe cases is due 
to the degeneration of neurons, white matter connections, or other co-morbidities as HIV-1 is a 
highly co-morbid disease49. 
 
Viral toxins 
Accumulation of HIV-1 toxins leads to the damage of neurons and the breakdown of 
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such synapses in the neurodegenerative HAND and similar dementia-associated diseases such as 
Alzheimer’s disease and psychiatric disorders. In the post-cART era HIV-1 rests more latently in 
the brain as patients treated for the virus have undetectable serum levels. cART’s inefficiency to 
treat the virus in the CNS and it’s harsh medicinal effects contribute to HAND and compound 
toxicity50. There are several other toxins from the virus that result in disease morphology in 
HAND: the envelope glycoproteins gp120, gp160 and gp41, the non-structural proteins Nef, the 
trans-activating gene and regulatory protein Tat which also regulates viral replication Rev, and 
another HIV-1 accessory protein vpr51. These toxins are most likely found within macrophages 
and microglial cells in MND and ANI HAND patients as these cells harbor latent virus with 
suppressive cART treatment52. The astrocytes role as a viral reservoir or toxin store for 
degradation and release, is one up for debate53. 
 
Transactivator of Transcription (Tat) and glycoprotein (gp120) 
Two of these toxins are popularly investigated in HAND systemically within the post-
cART era - gp120 and Trans-activator of transcription Tat. Tat and gp120 both target and effect 
separate components of brain cell biology to produce HAND, the immune related cells and 
vasculature for the former and major brain functioning neurons and astrocytes for the latter. Even 
though gp120 is toxic to endothelial cells of the BBB and is necessary to initiation of viral entry 
into the CNS especially in HIVE, it is found at higher levels within the serum rather than the 
CNS and has less effect in HAND without encephalitis54,55. Therefore, the toxic contributions of 
gp120 may occur early on to be masked by glutamate and Tat as its detection in HIV autopsy 
brains is low55. 
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Tat targets both neurons and astrocytes post secretion from infected macrophages and 
microglia within the Tat transgenic mouse model to cause disease pathology28,56. In astrocytes 
this includes, glial I brillar y acidic protein (GFAP) aggregation, lysosomal exocytosis, and 
glutamate excitotoxicity which contribute to neuronal cell death in HAND57.Tat produces similar 
effects in neurons altering GABA and glutamate neurotransmitter release with opposite effects 
on each; increasing glutamate via AMPA and acetylcholine receptors and decreasing GABA 
neurotransmitter release 58. The inhibition of neurotransmitter release was investigated in relation 
to the inositol 1,4,5 -triphosphate (IP3) pathway.  
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CHAPTER 5: CONCLUSION 
Accumulated Tat in the extra-cellular space is believed to increase intercellular calcium 
levels to dysregulate its influx and eventually lead to increased exocytosis of neurotransmitters 
and glutamate excitotoxicity. Increased membrane depolarization is initially mediated through 
the IP3 pathway which fuels the over activation and stress of neurons and astrocytes seen in the 
HAND phenotype 26,59 .Using chromaffin and PC12 neuroendocrine cells it was shown that Tat is 
trafficked intracellularly via endosomes to bind and sequester IP3, and eventually inhibit 
neurosecretion and associated proteins such as annexin A2 which promotes lipid microderm 
formation 60 . 
This study along with several others linked Tat to the endo- and exo-cytosis pathway 
within the periphery. This however, has not been shown within the CNS; but, a study analyzed 
Tat’s effect within neurons to show it increases mir-128 to inhibit vesicular proteins like SNAP-
25, a pre-synaptic protein, and SV2A the ubiquitous glycoprotein found within pre-synapses61 . 
This also verifies Tat’s pre-synaptic effects on neurons and its association to SV2A which 
corresponds with the negative Tat effect we show on 11C-UCB-J uptake and the ubiquitous pre-
synaptic density.  
Due to low n numbers and variability with the imaging process, we cannot conclude with 
great certainty that Tat significantly decreases SV2A expression as we still need to conduct 
dynamic analysis and kinetic modeling to analyze longitudinal effects of Tat on 11C-UCB-J and 
hence pre-synapses; but our data  indicate that Tat depreciates 11C-UCB-J’s target.  
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How and if Tat alters 11C-UCB-AJ’s bonding to SV2A is not analyzed, but an SV2A 
blocker or different sized Tat proteins could be used to see whether Tat interacts with SV2A and 
what portion of the protein is important for these effects would be a good study to examine this. 
Also, analysis of Tat’s effect ex vivo via western blot or immunohistochemistry would be a good 
follow up for verification. A recent study shows that CBD or epidiolex interacts with SV2A and 
would make a good blocker or drug to analyze. I propose that Tat interacts with SV2A and 
synaptotagmin as its mechanism of internalization through endocytosis to alter the endo- 
exocytosis pathway (not shown).  
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TABLES 
 
Table 1. Age, body weight and injection dose by genotype in Tat transgenic mice 
 Parameter/ 
Session 





n = 6 (3f) 
Baseline 95.8±4.22 3.2±0.14 25.2±3.53 404.0±26.43 
2 weeks 112.8±1.17 3.8±0.04 25.9±3.55 323.9±69.27 
3 months 181.8±1.17 6.1±0.04 30.4±2.18 324.1±40.51 
Tat (+) 
n = 5 (2f) 
Baseline 96.6±3.13 3.2±0.10 26.2±3.46 383.0±46.50 
2 weeks 112.6±0.55 3.8±0.02 27.6±3.34 330.0±100.22 
3 months 181.6±0.55 6.1±0.02 30.4±3.68 337.7±35.35 
Data are mean ± SD.  
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FIGURES 
 
Figure 1. Scheme showing the experimental design of the conducted study on timeline 
 
Figure 1. At 3 months of age Tat transgenic mice (n = 5-6 per group/3 males, 2-3 females) were 
PET imaged without having received DOX treatment (S1, baseline). Following PET imaging Tat 
transgenic mice were put on DOX treatment and PET imaged again after 2 weeks of DOX exposure 
(S2, 2 weeks DOX). The last PET imaging session as conducted after 3 months of DOX exposure 
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Figure 2. Time-activity SUV curves of [11C]-UCB-J PET over a 60 minute time period 
 
Figure 2. Average time-activity curves of [11C]-UCB-J PET representingi the standardized 
uptake value (SUV) for the cerebrum (black lines) and muscle (blue lines) over a 60 minute time 
period separately for (A) Tat(−) mice and (B) Tat(+) mice. All data are presented as mean ± SD 
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Figure 3. Decreased [11C]-UCB-J binding in a Tat(+) mouse compared to a Tat(−) mouse 
 
Figure 3. Representative overlay images of a Tat(−) mouse and a Tat(+) mouse show CT 
imaging (white) and PET imaging using the synaptic vesicle glycoprotein 2A (SV2A) selective 
radiotracer, [11C]-UCB-J (SUV scale, yellow-red). Both mice have been exposed to DOX for 3 
months. The Tat(+) mouse indicates a downregulation of [11C]-UCB-J uptake in the brain 
compared to the Tat(−) mouse, suggesting Tat expression decreases synaptic density. PET: 
positron emission tomography; CT: computed tomography; SUV: standard uptake value; DOX: 
doxycycline. 
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Figure 4. SUV brain/muscle ratio normalized to baseline (% change) at the static 17.5 minute 
time point  
 
Figure 4. SUV for brain/muscle ratio normalized to baseline (% change) at 17.5 minutes. (A) 
SUV brain/muscle ratio of [11C]-UCB-J uptake is represented over the three PET imaging 
sessions separate for Tat(−) and Tat(+) mice (n = 5-6 per group). A significant time x genotype 
interaction demonstrates a downregulation of SUV brain/muscle ratio over time for Tat(+) mice 
but not for Tat(−) mice. No other effect and/or interaction was significant, indicating that sex 
does not alter the SUV brain/muscle ratio at the static 17.5 minute time point. (B) SUV 
brain/muscle ratio of [11C]-UCB-J uptake is represented over the three PET imaging sessions 
separate for males only (n = 3 per group). No significant effect for genotype and/or time was 
noted. (C) SUV brain/muscle ratio of [11C]-UCB-J uptake is represented over the three PET 
imaging sessions separate for females only (n = 2-3 per group). No significant effect for 
genotype and/or time was noted. All data are presented as mean ± SD. #p = 0.031 Tat(+) at 
baseline no DOX (S1) vs. Tat(+) at 3 months DOX (S3); *p = 0.035 Tat(+) at 2 weeks DOX (S2) 
vs. Tat(+) at 3 months DOX (S3). min: minutes. 
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Figure 5. SUV brain/muscle ratio normalized to baseline (% change) at the static 25 minute time 
point  
 
Figure 5. SUV for brain/muscle ratio normalized to baseline (% change) at 25 minutes. (A) SUV 
brain/muscle ratio of [11C]-UCB-J uptake is represented over the three PET imaging sessions 
separate for Tat(−) and Tat(+) mice (n = 5-6 per group). A significant time x genotype 
interaction demonstrates a downregulation of SUV brain/muscle ratio over time for Tat(+) mice 
but not for Tat(−) mice. No other effect and/or interaction was significant, indicating that sex 
does not alter the SUV brain/muscle ratio at the static 25 minute time point. (B) SUV 
brain/muscle ratio of [11C]-UCB-J uptake is represented over the three PET imaging sessions 
separate for males only (n = 3 per group). No significant effect for genotype and/or time was 
noted. (C) SUV brain/muscle ratio of [11C]-UCB-J uptake is represented over the three PET 
imaging sessions separate for females only (n = 2-3 per group). No significant effect for 
genotype and/or time was noted. All data are presented as mean ± SD. #p = 0.031 Tat(+) at 
baseline no DOX (S1) vs. Tat(+) at 3 months DOX (S3). min: minutes. 
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Figure 6. SUV brain/muscle ratio normalized to baseline (% change) and averaged across the 
static 17.5 and 25 minute time points  
 
Figure 6. SUV for brain/muscle ratio normalized to baseline (% change) averaged across 17.5 
and 25 minutes. (A) SUV brain/muscle ratio of [11C]-UCB-J uptake is represented over the three 
PET imaging sessions separate for Tat(−) and Tat(+) mice (n = 5-6 per group). A significant time 
x genotype interaction demonstrates a downregulation of SUV brain/muscle ratio over time for 
Tat(+) mice but not for Tat(−) mice. No other effect and/or interaction was significant, indicating 
that sex does not alter the SUV brain/muscle ratio at 17.5 – 25 minutes. (B) SUV brain/muscle 
ratio of [11C]-UCB-J uptake is represented over the three PET imaging sessions separate for 
males only (n = 3 per group). No significant effect for genotype and/or time was noted. (C) SUV 
brain/muscle ratio of [11C]-UCB-J uptake is represented over the three PET imaging sessions 
separate for females only (n = 2-3 per group). No significant effect for genotype and/or time was 
noted. All data are presented as mean ± SD. #p = 0.024 Tat(+) at baseline no DOX (S1) vs. 
Tat(+) at 3 months DOX (S3); *p = 0.050 Tat(+) at 2 weeks DOX (S2) vs. Tat(+) at 3 months 
DOX (S3). min: minutes. 
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